米国市場銘柄情報

IXHL インカネックス・ヘルスケア

銘柄追加

2.400
+0.180+8.12%

取引中 04/29 13:02 ET

3,810.02万時価総額1.52直近PER

インカネックス・ヘルスケアに関するコメント

ログインコメントを投稿

Trytosaveabit

04/16 20:12

Update

$インカネックス・ヘルスケア(IXHL.US)$ Incannex Healthcare Inc: Intends to Submit Nda for Ihl-42X Fixed Dose Combination Drug to FDA Using 505(B)2 Pathway

Stock Region

02/29 06:57

Healthcare Company Announces Positive Clinical Trial Results For GAD

Incannex Announces Positive Topline Results from Phase 2 Psi-GAD1 Clinical Trial of Psilocybin in Generalised Anxiety Disorder.
In a significant development for the field of mental health, biopharmaceutical company Incannex Healthcare Limited (ASX: IHL) has announced positive topline results from its Phase 2 Psi-GAD1 clinical trial of psilocybin in Generalised Anxiety Disorder (GAD). $インカネックス・ヘルスケア(IXHL.US)$
stockregion.app...